FDA revisits new structure for drug review documents, aiming to better explain its decisions
Back in 2019, as part of a program focused on improving documentation and communications for drug approvals, the FDA made a change to how it …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
